Selected research
Industry Growth & Trends
Global APOL1 Mediated Kidney Disease Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global APOL1 Mediated Kidney Disease market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for APOL1 Mediated Kidney Disease is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for APOL1 Mediated Kidney Disease is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for APOL1 Mediated Kidney Disease is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the APOL1 Mediated Kidney Disease market include Teva Pharmaceuticals, Novartis, ZyVersa Therapeutics, Vertex Pharmaceuticals, Travere Therapeutics, Ionis Pharmaceuticals, GlaxoSmithKline and ChemoCentryx, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global APOL1 Mediated Kidney Disease market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The APOL1 Mediated Kidney Disease market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global APOL1 Mediated Kidney Disease market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to APOL1 Mediated Kidney Disease.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global APOL1 Mediated Kidney Disease market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
APOL1 Mediated Kidney Disease Market by Company
Teva Pharmaceuticals
Novartis
ZyVersa Therapeutics
Vertex Pharmaceuticals
Travere Therapeutics
Ionis Pharmaceuticals
GlaxoSmithKline
ChemoCentryx
APOL1 Mediated Kidney Disease Segment by Type
Small Molecule
Gene Modification
Nucleic Acid Therapies
Others
APOL1 Mediated Kidney Disease Segment by Application
Chronic Kidney Disease
End Stage Kidney Disease
APOL1 Mediated Kidney Disease Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global APOL1 Mediated Kidney Disease market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of APOL1 Mediated Kidney Disease and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of APOL1 Mediated Kidney Disease.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of APOL1 Mediated Kidney Disease companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Small Molecule
- Gene Modification
- Nucleic Acid Therapies
- Others
Applications
- Chronic Kidney Disease
- End Stage Kidney Disease
Companies covered
- Teva Pharmaceuticals
- Novartis
- ZyVersa Therapeutics
- Vertex Pharmaceuticals
- Travere Therapeutics
- Ionis Pharmaceuticals
- GlaxoSmithKline
- ChemoCentryx
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global APOL1 Mediated Kidney Disease Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global APOL1 Mediated Kidney Disease Market Size by Region (2021-2032)
- 1.4.1 Global APOL1 Mediated Kidney Disease Market Size by Region (2021-2026)
- 1.4.2 Global APOL1 Mediated Kidney Disease Market Size by Region (2027-2032)
- 1.5 Key Regions APOL1 Mediated Kidney Disease Market Size (2021-2032)
- 1.5.1 North America APOL1 Mediated Kidney Disease Market Size Growth Rate (2021-2032)
- 1.5.2 Europe APOL1 Mediated Kidney Disease Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific APOL1 Mediated Kidney Disease Market Size Growth Rate (2021-2032)
- 1.5.4 South America APOL1 Mediated Kidney Disease Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa APOL1 Mediated Kidney Disease Market Size Growth Rate (2021-2032)
2 APOL1 Mediated Kidney Disease Market by Type
- 2.1 Type Introduction
- 2.1.1 Small Molecule
- 2.1.2 Gene Modification
- 2.1.3 Nucleic Acid Therapies
- 2.1.4 Others
- 2.2 Global APOL1 Mediated Kidney Disease Market Size by Type
- 2.2.1 Global APOL1 Mediated Kidney Disease Market Size Overview by Type (2021-2032)
- 2.2.2 Global APOL1 Mediated Kidney Disease Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global APOL1 Mediated Kidney Disease Market Size Forecasted by Type (2027-2032)
- 2.3 Global APOL1 Mediated Kidney Disease Market Size by Regions
- 2.3.1 North America APOL1 Mediated Kidney Disease Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe APOL1 Mediated Kidney Disease Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific APOL1 Mediated Kidney Disease Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America APOL1 Mediated Kidney Disease Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa APOL1 Mediated Kidney Disease Market Size Breakdown by Type (2021-2026)
3 APOL1 Mediated Kidney Disease Market by Application
- 3.1 Type Introduction
- 3.1.1 Chronic Kidney Disease
- 3.1.2 End Stage Kidney Disease
- 3.2 Global APOL1 Mediated Kidney Disease Market Size by Application
- 3.2.1 Global APOL1 Mediated Kidney Disease Market Size Overview by Application (2021-2032)
- 3.2.2 Global APOL1 Mediated Kidney Disease Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global APOL1 Mediated Kidney Disease Market Size Forecasted by Application (2027-2032)
- 3.3 Global APOL1 Mediated Kidney Disease Market Size by Regions
- 3.3.1 North America APOL1 Mediated Kidney Disease Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe APOL1 Mediated Kidney Disease Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific APOL1 Mediated Kidney Disease Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America APOL1 Mediated Kidney Disease Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa APOL1 Mediated Kidney Disease Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 APOL1 Mediated Kidney Disease Industry Trends
- 4.2 APOL1 Mediated Kidney Disease Industry Drivers
- 4.3 APOL1 Mediated Kidney Disease Industry Opportunities and Challenges
- 4.4 APOL1 Mediated Kidney Disease Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by APOL1 Mediated Kidney Disease Revenue (2021-2026)
- 5.2 Global APOL1 Mediated Kidney Disease Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global APOL1 Mediated Kidney Disease Key Company Headquarters & Area Served
- 5.4 Global APOL1 Mediated Kidney Disease Company, Product Type & Application
- 5.5 Global APOL1 Mediated Kidney Disease Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global APOL1 Mediated Kidney Disease Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 APOL1 Mediated Kidney Disease Players Market Share by Revenue in 2025
- 5.6.3 2025 APOL1 Mediated Kidney Disease Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Teva Pharmaceuticals
- 6.1.1 Teva Pharmaceuticals Company Information
- 6.1.2 Teva Pharmaceuticals Business Overview
- 6.1.3 Teva Pharmaceuticals APOL1 Mediated Kidney Disease Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Teva Pharmaceuticals APOL1 Mediated Kidney Disease Product Portfolio
- 6.1.5 Teva Pharmaceuticals Recent Developments
- 6.2 Novartis
- 6.2.1 Novartis Company Information
- 6.2.2 Novartis Business Overview
- 6.2.3 Novartis APOL1 Mediated Kidney Disease Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Novartis APOL1 Mediated Kidney Disease Product Portfolio
- 6.2.5 Novartis Recent Developments
- 6.3 ZyVersa Therapeutics
- 6.3.1 ZyVersa Therapeutics Company Information
- 6.3.2 ZyVersa Therapeutics Business Overview
- 6.3.3 ZyVersa Therapeutics APOL1 Mediated Kidney Disease Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 ZyVersa Therapeutics APOL1 Mediated Kidney Disease Product Portfolio
- 6.3.5 ZyVersa Therapeutics Recent Developments
- 6.4 Vertex Pharmaceuticals
- 6.4.1 Vertex Pharmaceuticals Company Information
- 6.4.2 Vertex Pharmaceuticals Business Overview
- 6.4.3 Vertex Pharmaceuticals APOL1 Mediated Kidney Disease Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Vertex Pharmaceuticals APOL1 Mediated Kidney Disease Product Portfolio
- 6.4.5 Vertex Pharmaceuticals Recent Developments
- 6.5 Travere Therapeutics
- 6.5.1 Travere Therapeutics Company Information
- 6.5.2 Travere Therapeutics Business Overview
- 6.5.3 Travere Therapeutics APOL1 Mediated Kidney Disease Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Travere Therapeutics APOL1 Mediated Kidney Disease Product Portfolio
- 6.5.5 Travere Therapeutics Recent Developments
- 6.6 Ionis Pharmaceuticals
- 6.6.1 Ionis Pharmaceuticals Company Information
- 6.6.2 Ionis Pharmaceuticals Business Overview
- 6.6.3 Ionis Pharmaceuticals APOL1 Mediated Kidney Disease Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Ionis Pharmaceuticals APOL1 Mediated Kidney Disease Product Portfolio
- 6.6.5 Ionis Pharmaceuticals Recent Developments
- 6.7 GlaxoSmithKline
- 6.7.1 GlaxoSmithKline Company Information
- 6.7.2 GlaxoSmithKline Business Overview
- 6.7.3 GlaxoSmithKline APOL1 Mediated Kidney Disease Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 GlaxoSmithKline APOL1 Mediated Kidney Disease Product Portfolio
- 6.7.5 GlaxoSmithKline Recent Developments
- 6.8 ChemoCentryx
- 6.8.1 ChemoCentryx Company Information
- 6.8.2 ChemoCentryx Business Overview
- 6.8.3 ChemoCentryx APOL1 Mediated Kidney Disease Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 ChemoCentryx APOL1 Mediated Kidney Disease Product Portfolio
- 6.8.5 ChemoCentryx Recent Developments
7 North America
- 7.1 North America APOL1 Mediated Kidney Disease Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America APOL1 Mediated Kidney Disease Market Size by Country (2021-2026)
- 7.3 North America APOL1 Mediated Kidney Disease Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe APOL1 Mediated Kidney Disease Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe APOL1 Mediated Kidney Disease Market Size by Country (2021-2026)
- 8.3 Europe APOL1 Mediated Kidney Disease Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific APOL1 Mediated Kidney Disease Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific APOL1 Mediated Kidney Disease Market Size by Country (2021-2026)
- 9.3 Asia-Pacific APOL1 Mediated Kidney Disease Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America APOL1 Mediated Kidney Disease Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America APOL1 Mediated Kidney Disease Market Size by Country (2021-2026)
- 10.3 South America APOL1 Mediated Kidney Disease Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa APOL1 Mediated Kidney Disease Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa APOL1 Mediated Kidney Disease Market Size by Country (2021-2026)
- 11.3 Middle East & Africa APOL1 Mediated Kidney Disease Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst